As per the NORD, Frontotemporal degeneration affects around 50,000-60,000 people in the United States. As per the DelveInsight, the total number of Frontotemporal prevalent cases in the seven major markets was found to be 76,499 in the year 2017.
The Frontotemporal Dementia market is expected to increase with a CAGR of 21.41% for the seven major markets [i.e. the USA, EU5 ( the UK, Germany, France, Italy, and Spain)] during the study period.
Some of the key pharma companies such as TauRx Therapeutics, Axon Neuroscience SE, Prevail Therapeutics, Avid Radiopharmaceuticals, and Alector are actively working to build up the Frontotemporal dementia pipeline.
For more detailed information on Frontotemporal dementia market, visit:
https://www.delveinsight.com/blog/frontotemporal-dementia-market/